Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Q4 2021 Earnings Presentation
19 slides from Therapeuticsmd's earnings presentation, Mar 10, 2022
Slide 1: Building the Premier Women's Health Company Q4 2021 Earnings
Building the Premier Women’s Health Company Q4 2021 Earnings March 10, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, t
Slide 3: Immediate Priorities
Drive top-line growth and overall operating performance Address capital structure to ease restrictive revenue and cash covenants currently in place Immediate Priorities Eliminate $60 million from our annual cost base, including the successful divestiture of vitaCare Achieve EBITDA breakeven in the s
Slide 4: ANNOVERA Manufacturing Update
ANNOVERA Manufacturing Update 1 3 2 4 What Happened Supply disruptions due to a higher rate of batch rejections associated with a restrictive specification for one test method FDA issued a CRL for our request to revise the product release specifications Where Are We Today Responded to FDA comments a
Slide 5: Delivering on Our Mission
5 Delivering on Our Mission Fulfill our commitment to reduce our annual cost base by $60 million Positioned to bring the Company to profitability and restructure our capitalization Successfully scale, manufacture and supply our flagship product, ANNOVERA Deliver results to our shareholders and provi
Slide 6: Q4 Financial Overview
TherapeuticsMD” 1 1 . For Her: For Life. Q4 21 Financial Overview
Slide 7: Amended Credit Agreement
7 Amended Credit Agreement Sixth Street Credit Agreement amended to: Adjust the $60 million-dollar minimum cash covenant Waive the fourth quarter covenant default and eliminate the 1st quarter 2022 revenue covenant Pay the first $120 million dollars of net proceeds of the vitaCare divestiture to Six
Slide 8: Quarterly Product Revenue Trends
$18.7 Quarterly Product Revenue (YoY) Quarterly Product Revenue Trends Millions 4Q21 Highlights Total net product revenue decreased 17% in Q421 vs Q420 ANNOVERA net revenue decreased 14% in Q421 vs Q420 and was significantly impacted by production and supply issues IMVEXXY net revenue decreased 24%
Slide 9: Financial Results: Comparison Q4 2021 to Q4 2020
Financial Results: Comparison Q4 2021 to Q4 2020 Gross margin of 75% in Q421 stable as compared to Q420 Operating expenses in Q421 decreased $2.3M from Q420 and included $4.5M in severance related to the exit of a former executive Net loss in Q421 decreased by $4.5M from Q321 and increased by $0.9M
Slide 10: Q4 2021 Commercial Overview
10 Q4 2021 Commercial Overview
Slide 11: ANNOVERA Quarterly TRx
ANNOVERA Quarterly TRx +11% Source: Symphony Metys – December 2021 Performance
Slide 12: ANNOVERA Prescribers: Launch to Date
ANNOVERA Prescribers: Launch to Date Source: Symphony Metys – December 2021; 5 prescribers in Q319 New prescribers defined as not having written Annovera in prior periods
Slide 13: IMVEXXY Quarterly TRx
IMVEXXY Quarterly TRx Source: Symphony Metys – December 2021
Slide 14: BIJUVA Quarterly TRx
BIJUVA Quarterly TRx Source: Symphony Metys – December 2021
Slide 15: Major Retargeting Focuses on High Decile Market Writers
Major Retargeting Focuses on High Decile Market Writers 15
Slide 16: New Focus
New Focus 16 Total Targets: ~14.7k 6% of targets aligned to the 103 territories prescribe all three TXMD products ANNOVERA : BC Market Coverage: 39% BIJUVA: VMS Market Coverage: 31% IMVEXXY: VVA Market Coverage: 36% Source - ADHOC_TMD_BCC_SW_PP_DATA_20211001.txt.gz Based upon 6 calls during first 6
Slide 17: Optimizing Alignment – 88% to Lie in Balanced Range
Optimizing Alignment– 88% to Lie in Balanced Range Index Distribution Target Coverage2 Previous Alignment 47 territories in the range of 900 – 1,100 index points 3 Index Distribution Target Coverage2 Index is calculated based on workload i.e. total calls in a territory, depending upon HCPs target se
Slide 18: Marketing – Maintain Consistent Effective Approach with HCPs and Consumers
Marketing – Maintain Consistent Effective Approach with HCP’s and Consumers DTC Benchmark ANNOVERA DTC Effective campaign featuring Whitney Cummings ANNOVERA HCP Procedure-Free Alternative to LARC Strategy Driving Continued Growth in Awareness
Slide 19: TherapeuticsMD – For Her. For Life.
TherapeuticsMD” For Her: For Life.